Table 1: Hypopigmented mycosis fungoides: patient demographics, clinical manifestations, and response to therapy.

Patients’ index numberAge at diagnosis/onset (years)GenderInitial diagnosisSite of skin involvement% of skin involvement at the time of diagnosislymph nodes (LN), liver (Liv), spleen (Sp)Stage at diagnosisPrevious treatmentsType of therapy givenResponse to therapy

1 (Figure 1)13/10FPVBoth lower and upper limbs, vitiligo-like lesions on buttocks30%L/axillary LN 0.5–1 cm diameter1BTopical antifungalNB-UVB 32 (3x/wk)CR

2 (Figure 2)29/26MPVAll 4 limbs, buttock, a few patches on trunk40%None1BTopical antifungalPUVA 36 (2x/wk)CR

3 (Figure 3)11/08MEczema, vitiligoVitiligo-like patches on buttocks<10%None1ATopical steroids, 10% coal tar lotion and sun light exposurePotent topical steroids daily for 12 monthsPR

4 (Figure 4)30/27FPV, PMHAll 4 limbs flexure aspect, anterior and back of trunk, breast30%None1BTopical antifungalNB-UVB 36 (3x/wk)CR

5 (Figure 5)29/24FPV, vitiligoTrunk, all 4 limbs40%None1BTopical antifungalNB-UVB 32 (3x/wk)PR

M—male, F—female, MF—mycosis fungoides, NB-UVB—narrowband ultraviolet B, PUVA—psoralen plus ultraviolet A, PV—Pityriasis versicolor, PLC—pityriasis lichenoides chronica, PMH—progressive macular hypomelanosis, NR—no clinical response, PR—partial clinical response, CR—complete clinical response.